TWD
BCRX icon

True Wealth Design’s BioCryst Pharmaceuticals BCRX Stock Holding History

True Wealth Design’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46K Buy
+946
New +$8.55K ﹤0.01% 1077
2025
Q4 		– Sell
-39
Closed -$297 – 2584
2025
Q3 		$297 Sell
39
-64
-62% -$533 ﹤0.01% 2195
2025
Q2 		$923 Sell
103
-1,145
-92% -$10.7K ﹤0.01% 1507
2025
Q1 		$9.36K Buy
1,248
+961
+335% +$7.75K ﹤0.01% 490
2024
Q4 		$2.16K Sell
287
-502
-64% -$3.81K ﹤0.01% 716
2024
Q3 		$6K Buy
+789
New +$6K ﹤0.01% 526

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

True Wealth Design's BCRX Position: Q2 2026 in Review

True Wealth Design opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 946 shares worth $9.46K. The stake represents ﹤0.01% of the portfolio and ranks #1077 among its holdings. This is a return to the name: True Wealth Design previously reported a position in BCRX as recently as Q3 2025.

True Wealth Design first reported a position in BCRX in Q3 2024 and has held it in 6 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • True Wealth Design held 946 shares of BioCryst Pharmaceuticals worth $9.46K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new True Wealth Design position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1077 holding.
  • True Wealth Design first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.